With Pix, Nequi, and Mercado Pago among the most used payment methods by Eneba’s customers, the operation now covers eight countries in the region
CURITIBA, BRAZIL – Media OutReach Newswire – 13 November 2026 – EBANX, a global technology company specializing in payment services for emerging markets, and Eneba, a Global digital marketplace for video games, have expanded their partnership across eight Latin American countries, building a payment portfolio around the local methods consumers use in each market.
The partnership began in 2023 across Brazil, Mexico, Colombia, Chile, Peru, Ecuador and Bolivia, with Argentina added the following year. In 2026, the collaboration reached a new milestone: through October, Eneba's processed volume through EBANX in Latin America grew 138% compared with the same period in 2025, more than doubling year over year.
Since 2023, Eneba has expanded its payment offering in these markets by combining credit and debit cards with alternative payment methods (APMs), including digital wallets such as Mercado Pago and Colombia's Nequi; instant payment systems such as Pix in Brazil and SPEI in Mexico; and cash-based methods such as Brazil's Boleto Bancário, Mexico's OXXO Pay, and Peru's PagoEfectivo.
"EBANX has been a strong partner in supporting our growth across Latin America. Their consistent performance and extensive coverage of local payment methods have helped us reflect consumer preferences in each market," said Mantas Eitutis, Head of Payments and Fraud at Eneba.
Local payments as a growth engine
The growth comes as digital payments continue to expand in Latin America. Across the region, about 25% of adults own a credit card, while 51% have already made a digital payment, according to the World Bank. That figure has risen from 34% in ten years, underscoring the growing role of instant payments and digital wallets in online commerce.
Eneba's results in Latin America reflect that relevance. Throughout 2026, the company recorded consistent growth in transaction volumes across key local payment methods, including Pix in Brazil, Nequi in Colombia, and SPEI in Mexico.
"There is no single payment playbook for Latin America. For global merchants, scaling across the region means understanding the differences and adapting the checkout to how consumers already pay," said James Booth, VP Commercial at EBANX.
Hashtag: #EBANX #Eneba #Gaming #LatAm #Payments
The issuer is solely responsible for the content of this announcement.
ABOUT EBANX
EBANX is the leading payments platform connecting global businesses to the world's fastest-growing digital markets. Founded in 2012 in Brazil, EBANX was built with a mission to expand access to international digital commerce. Leveraging proprietary technology, deep market expertise, and robust infrastructure, EBANX enables global companies to offer hundreds of local payment methods across Latin America, Africa, and Asia. More than just payments, EBANX drives growth, enhances sales, and delivers seamless purchase experiences for businesses and end-users alike.
For further information, please visit:
Website: https://www.ebanx.com/en/
LinkedIn: https://www.linkedin.com/company/ebanx
ABOUT ENEBA
Eneba is a digital marketplace for video games that has served over 15 million buyers. Founded in 2018, Eneba has rapidly grown into a trusted ecosystem for gamers with game keys, gift cards, and mobile top-ups at the best prices, backed by robust customer support and fraud prevention measures.
For further information, please visit:
Website: http://eneba.com/
LinkedIn: https://www.linkedin.com/company/enebagames/
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
How local payments are driving growth for Eneba in LatAm
Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path. Proceeds will be deployed to advance the core product ICVAX® for HIV and to accelerate the development of the immunotherapy pipeline for cancers across the vaccine and antibody programmes.
ICVAX® has completed a randomised, placebo-controlled NMPA-approved Phase I clinical trial in people living with HIV on antiretroviral therapy, with favourable safety and immunogenicity performance. The program is advancing to Phase II clinical trial for efficacy evaluation for a more durable immune control of HIV and the target path to functional cure.
"This funding round marks an important step in Yicura's growth as we move ICVAX® from early clinical validation towards efficacy studies," Dr. Xia JIN, Co-Founder and CEO of Yicura, said. "We are encouraged by the Phase I data of ICVAX® and the potential of our PD-1-enhanced DNA vaccine and anti-∆42PD1 antibody platforms to address serious unmet needs in infectious diseases, cancers and inflammation. We are grateful for Gobi Partners' partnership and the investors' confidence in our science, our team and our mission to develop immunotherapies that can meaningfully change the standard of care for patients."
"Yicura is building a distinctive suite of immunotherapies from Hong Kong, with a clear clinical lead in ICVAX® and platform technologies that can extend well beyond a single indication to precision therapies for cancers." Mr. Fred LI, Managing Director and Head of University Ventures of Gobi Partners, shared, "We are pleased to lead this Series B financing and to support Dr. JIN and the Yicura team as they advance the promising HIV therapeutic vaccine and continue to translate their brilliant technologies into medicines for patients in need."
Hashtag: #醫克生物 #Yicura
http://www.yicura.hk
https://www.linkedin.com/company/yicura
The issuer is solely responsible for the content of this announcement.
About Yicura BioMed (formerly known as Immuno Cure)
Yicura BioMed ("Yicura") is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.
To learn more about Yicura, please visit: http://www.yicura.hk
About Gobi Partners
Founded in 2002, Gobi Partners is a leading pan-Asian investment firm specialising in bespoke capital solutions for family offices, sovereign wealth funds, financial institutions and corporate investors. Headquartered in Hong Kong and Kuala Lumpur, Gobi manages US$2 billion across 30+ investment vehicles, investing in early to growth-stage companies with the potential for generational and global impact.
The firm's team of over 90 investment professionals operates from 18 locations, curating a diversified portfolio of more than 400 companies, with 76 exits achieved to date. Gobi is recognised for its long-term, values-aligned approach, building ecosystems at the intersection of technology, sustainability, and inclusion. From pioneering TaqwaTech for two billion Muslims, to advancing the circular economy, to promoting gender-diverse leadership, Gobi backs the trends that are reshaping societies.
Gobi's edge lies in identifying structural and demographic shifts, forging partnerships with universities and institutions of higher education; bridging world-class research with private capital and bringing deep technology breakthroughs to commercialisation.
Official Website: https://gobi.vc
Official Linkedin: https://www.linkedin.com/company/gobipartners/
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
